Abstract library

8 results for "Ruzzenente".
#1007 Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study
Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
#1198 Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical Series
Introduction: PanNETs have a broad spectrum of aggressiveness. Somatostatin-receptor based functional imaging, [68Ga]DOTATOC-PET/CT (GP), is recommended in the diagnostic workup of PanNETs; preliminary evidences show that [18F]FDG-PET/CT (FP) can provide prognostic information.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.
Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#1447 Clinicopathologic Features, Management and Outcome of Neuroendocrine Tumors (NETs) in MEN1: The Verona Multidisciplinary PlaNET Group
Introduction: Gastroenteropancreatic endocrine tumors (GEP-NETs) are a frequent manifestation of MEN1. They represent an important prognostic factor in these patients. There is still a debate on their management, mainly on surgical strategy, due to their multicentricity and high recurrence rate.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Elisa Cosaro
Keywords: MEN1, GEP-NET, management
#1481 Neuroendocrine Liver Metastasis: A Novel Nomogram to Predict Patient’s Prognosis After Liver Resection
Introduction: Despite surgery remains the only potentially curative option for patients with neuroendocrine liver metastases (NELMs), the factors determining the prognosis of patients following hepatectomy are poorly understood.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Fabio Bagante
#2274 Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria
Introduction: Liver transplantation (LT) has been prosed as a curative treatment for metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) but there is a lack of consensus on its real benefit when compared with hepatectomy.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Andrea Ruzzenente